- Home
- HCI vs VRDN Comparison
HCI vs VRDN Comparison
Compare HCI & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCI | VRDN |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | 552 | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | HCI | VRDN |
|---|---|---|
| Price | $155.58 | $27.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $230.00 | $40.92 |
| AVG Volume (30 Days) | 99.6K | ★ 973.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $11.44 | $27.65 |
| Revenue Next Year | $7.67 | $253.29 |
| P/E Ratio | $9.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $129.58 | $9.90 |
| 52 Week High | $210.50 | $34.29 |
Technical Indicators
Market Signals| Indicator | HCI | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 40.54 |
| Support Level | $151.72 | $26.31 |
| Resistance Level | $158.85 | $33.71 |
| Average True Range (ATR) | 4.94 | 1.14 |
| MACD | -1.33 | -0.10 |
| Stochastic Oscillator | 23.02 | 23.59 |
Price Performance
Historical ComparisonAbout HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).